Lelia Delamarre

Title: Lelia Delamarre: Innovator in Immunogenic Peptide Identification

Introduction

Lelia Delamarre is a prominent inventor based in San Francisco, CA (US). She has made significant contributions to the field of immunotherapy, particularly in the identification of disease-specific immunogenic peptides. With a total of 2 patents, her work is paving the way for advancements in personalized medicine.

Latest Patents

Delamarre's latest patents focus on the identification of immunogenic mutant peptides using genomic, transcriptomic, and proteomic information. The methods disclosed in her patents provide a series of selection steps to identify disease-specific immunogenic peptides. These immunogenic epitopes are particularly applicable for use in peptide-based immunotherapy, especially in cancer therapy. Furthermore, her methods can be performed in a high-throughput manner, serving as a means for personalized vaccine development and therapy. The patents also include compositions of immunogenic peptides and methods of treatment comprising these compositions.

Career Highlights

Throughout her career, Lelia Delamarre has worked with notable companies such as Genentech, Inc. and F. Hoffmann-La Roche AG. Her experience in these leading biotechnology firms has contributed to her expertise in the field of immunology and peptide research.

Collaborations

Delamarre has collaborated with esteemed colleagues, including Patrick J. Lupardus and Ira Mellman. These collaborations have further enhanced her research and development efforts in immunogenic peptide identification.

Conclusion

Lelia Delamarre's innovative work in the identification of immunogenic peptides is making a significant impact in the field of cancer therapy and personalized medicine. Her contributions are essential for the advancement of peptide-based immunotherapy, and her patents reflect her commitment to improving treatment options for patients.